Atropos Health and SEQSTER collaborate to streamline patient registry deployment and expand real-world evidence accessibility

Atropos Health and SEQSTER have partnered to simplify the establishment of patient registries and enhance the availability of real-world evidence (RWE), accelerating evidence generation and driving advancements in research for underserved populations.

Atropos Health, a leader in real-world evidence (RWE) generation, and SEQSTER, a patient-centric healthcare data technology company, have joined forces in a strategic partnership aimed at simplifying the establishment of patient registries and expanding the availability of RWE. This partnership aims to streamline the process for healthcare and life science organizations to establish patient registries, accelerating evidence generation, driving research advancements for underrepresented populations, and reducing costs associated with registry deployment.

Through the collaboration, SEQSTER will integrate its patient registry infrastructure with the Atropos Health Evidence Network, enabling organizations to swiftly deploy and manage patient registries. This will enable researchers to access a broader range of patient data, leading to more comprehensive and reliable RWE.

“Our partnership with Atropos Health furthers our commitment to progressing health care with novel technology and providing real world data and rapid evidence generation accessible to both patients and partners,” emphasized Ardy Arianpour, Co-founder and CEO of SEQSTER. “SEQSTER’s operating system acts as a digital front door for patients and researchers. By powering the Atropos Health Evidence Network with longitudinal patient data, we’ll be able to save health systems and life science enterprises cost and time on registry deployment, making it a seamless process for all stakeholders. Now, we can deliver real-time, real-world data and layer in AI to accelerate drug discovery and provide deep insights for our pharma and health system customers.”

Dr Brigham Hyde, Co-founder and CEO of Atropos Health, highlighted the partnership’s significance in supporting the analysis of registry data and rapidly deploying registries for various initiatives, “Atropos Health is the fastest way to convert methodologically sound evidence from real-world data – for researchers, patient care, existing data platforms, and now, clinical development. With SEQSTER, we add the ability not only to support analysis of registry data to the growing variety of real-world data sources available on the Atropos Health Evidence Network, but we can also support health system and life science customers’ ability to rapidly stand up registries to support a variety of initiatives. Speed-to-setup and speed-to-insight through this combination is unprecedented, and should drive critical evidence for underrepresented populations.”

This collaboration follows Atropos Health’s recent entry into the life sciences market through a partnership with Janssen Research & Development. The company also launched its Geneva OS™ and ChatRWD™ user application, the first Generative AI application with direct chat-to-database capability, to assist healthcare and life science leaders in propelling and accelerating evidence generation.